Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: …
6 days ago · NKTR. Revenue: $24.1 million for Q3 2024. Full Year Revenue Guidance: Expected between $90-95 million. Cash and Investments: $249 million at the end of Q3 2024. Net Loss: $37 million or $0.18 per ...
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts …
3 days ago · NKTR. Nektar Therapeutics (NASDAQ:NKTR) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$24m beat estimates by a substantial 32% ...
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in …
5 days ago · In This Article: NKTR. NVS. Nektar Therapeutics NKTR incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 23 cents. In the ...
Nektar and Collaborators Present Late-breaking Results from …
6 days ago · Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 07, 2024 at 10:16 am EST.
Nektar Therapeutics to Participate in Upcoming Investor …
SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here.
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Sep 30, 2024 · SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are ...
Press Releases - Nektar Therapeutics
Oct 17, 2024 · Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Nektar Announces Definitive Agreement with Ampersand Capital …
Nov 4, 2024 · Ampersand has agreed to acquire Nektar's commercial-scale manufacturing facility and PEGylation reagent supply business for a total consideration of $90 million, comprised of $70 million in cash...
Nektar presents late-breaking results from Phase 2 Study of NKTR …
Nov 7, 2024 · Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M Seeking Alpha 2d Nektar releases promising phase 2 results for NKTR-255 in lymphopenia
Eczema Drug Developer Nektar Gains Analyst Confidence With …
Nov 4, 2024 · Piper maintains a high probability of success for 36-week Phase 2b REZOLVE-AA n=84 Alopecia areata (AA) patients, with topline data expected in the first half of 2025. Piper initiates with an ...
- Some results have been removed